Jennifer Wallet

Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial

Olivier Mir, Thomas Brodowicz, Antoîne Italiano et al. · The Lancet Oncology · 2016 · 276 citations

Oncology, Metronomic Therapy, Clinical Trials +5

Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program

Antoine Adenis, Christelle de la Fouchardière, Bernard Paule et al. · BMC Cancer · 2016 · 126 citations · Full text

Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer

Émilie Le Rhun, Jennifer Wallet, Audrey Mailliez et al. · Neuro-Oncology · 2019 · 101 citations · Full text

<scp>REGOSARC</scp>: Regorafenib versus placebo in doxorubicin‐refractory soft‐tissue sarcoma—A quality‐adjusted time without symptoms of progression or toxicity analysis

Vincent Berry, Laurent Basson, Emilie Bogart et al. · Cancer · 2017 · 42 citations · Full text

Stereotactic Re-irradiation for Local Recurrence in the Prostatic Bed After Prostatectomy: Preliminary Results

Jonathan Olivier, Laurent Basson, Philippe Puech et al. · Frontiers in Oncology · 2019 · 32 citations · Full text